1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2016

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 71 pages

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2016’, provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
- The report reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Onychomycosis (Tinea Unguium) therapeutics and enlists all their major and minor projects
- The report assesses Onychomycosis (Tinea Unguium) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Onychomycosis (Tinea Unguium) Overview 8
Therapeutics Development 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9
Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 10
Onychomycosis (Tinea Unguium) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Onychomycosis (Tinea Unguium) - Products under Development by Companies 15
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 16
Eisai Co., Ltd. 16
Helix BioMedix, Inc. 17
Hexima Limited 18
Meiji Seika Pharma Co., Ltd. 19
Moberg Pharma AB 20
NAL Pharmaceuticals Ltd. 21
Nihon Nohyaku Co., Ltd. 22
Novabiotics Limited 23
Nuvo Research Inc. 24
Polichem S.A. 25
Viamet Pharmaceuticals, Inc. 26
Onychomycosis (Tinea Unguium) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ELS-160 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
fosravuconazole - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
HB-1275 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
HXP-124 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
luliconazole - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
ME-1111 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
NAL-3216 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
NP-213 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
terbinafine - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
terbinafine - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
terbinafine - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
VT-1161 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 54
Onychomycosis (Tinea Unguium) - Dormant Projects 60
Onychomycosis (Tinea Unguium) - Discontinued Products 63
Onychomycosis (Tinea Unguium) - Product Development Milestones 64
Featured News and Press Releases 64
Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015 64
Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit 65
Aug 11, 2015: Nuvo Research Announces Grant of United States Patent for Topical Onychomycosis Formulation 65
Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus) 65
Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology 66
Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis 66
Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis 67
Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 68
Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 68
Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Comparative Analysis by Unknown Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H1 2016 16
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H1 2016 17
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Limited, H1 2016 18
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 19
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2016 20
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 21
Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H1 2016 22
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Limited, H1 2016 23
Onychomycosis (Tinea Unguium) - Pipeline by Nuvo Research Inc., H1 2016 24
Onychomycosis (Tinea Unguium) - Pipeline by Polichem S.A., H1 2016 25
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Onychomycosis (Tinea Unguium) Therapeutics - Recent Pipeline Updates, H1 2016 54
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2016 60
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..1), H1 2016 61
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H1 2016 62
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2016 63

List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Targets, H1 2016 28
Number of Products by Stage and Targets, H1 2016 28
Number of Products by Mechanism of Actions, H1 2016 30
Number of Products by Stage and Mechanism of Actions, H1 2016 30
Number of Products by Routes of Administration, H1 2016 32
Number of Products by Stage and Routes of Administration, H1 2016 32
Number of Products by Molecule Types, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.